Telmisartan: Contraindicated in 2nd and 3rd trimesters of pregnancy and lactation.
Use in pregnancy: Female patients of childbearing age should be told about the consequences of 2nd and 3rd trimester exposure to drugs that act on the renin-angiotensin system, and they should also be told that these consequences do not appear to have resulted from intrauterine drug exposure that has been limited to the 1st trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.
Use in lactation: It is not known whether telmisartan is excreted in human milk, but telmisartan was shown to be present in the milk of lactating rats. Thiazides appear in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.